2,2-Dimethyl-3-buten-1-yl-acetat | 926-33-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2,2-Dimethyl-3-buten-1-yl-acetat
• 英文别名: acetic acid-(2,2-dimethyl-but-3-enyl ester)；Essigsaeure-(2,2-dimethyl-but-3-enylester)；2,2-dimethyl-3-butenyl acetate；2,2-Dimethylbut-3-enyl acetate
• CAS: 926-33-0
• 化学式: C₈H₁₄O₂
• 分子量: 142.198
• InChiKey: QNUFWHGRCFSIJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  四溴化碳 、 2,2-Dimethyl-3-buten-1-yl-acetat 在 过氧化苯甲酰 作用下， 以17.3 g (36.5 mmol; 73%)的产率得到2,2-dimethyl-3,5,5,5-tetrabromopentyl acetate
  参考文献：
  名称：

  Process for the preparation of 1,1-dihalo-4-methyl-1,3-pentadiene

  摘要：

  制备1,1-二卤代-4-甲基-1,3-戊二烯化合物的过程包括将公式##STR1##中的2-2-二甲基-3,5,5,5-四卤代戊-1-基衍生物与具有在20℃至160℃温度范围内的碱性反应的物质反应。其中Hal.sup.1如上所述，Hal.sup.2为卤素，R为氢或碳数不超过5的烷酰基。在这种过程中产生的某些中间体也可以用作初始起始物质。

  公开号：

  US04191712A1

文献信息

• USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
  申请人：GENENTECH, INC.

  公开号：US20130095172A1

  公开（公告）日：2013-04-18

  The present application describes uses for and articles of manufacture including Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity; treating early-stage HER2-positive breast cancer; treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag; treating HER2-positive metastatic gastric cancer; treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and Vinorelbine; treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and aromatase inhibitor; and treating low HER3 ovarian, primary peritoneal, or fallopian tube cancer. It also describes an article of manufacture comprising a vial with Pertuzumab therein and a package insert providing safety and/or efficacy data thereon; a method of making the article of manufacture; and a method of ensuring safe and effective use of Pertuzumab related thereto. In addition the application describes an intravenous (IV) bag containing a stable mixture of Pertuzumab and Trastuzumab suitable for administration to a cancer patient.
• ARTICLES OF MANUFACTURE AND METHODS FOR CO-ADMINISTRATION OF ANTIBODIES
  申请人：Genentech, Inc.

  公开号：US20130195851A1

  公开（公告）日：2013-08-01

  The present invention relates to articles of manufacture and methods for co-administration of antibodies and/or antibody-like molecules, and further concerns methods for intravenous administration of more than one antibody and/or antibody-like molecule to a subject in need from a stable mixture contained in the same article of manufacture, such as an intravenous infusion bag (IV bag).
• US4191712A
  申请人：——

  公开号：US4191712A

  公开（公告）日：1980-03-04